US 11,926,622 B2
Fluoroalkyl-oxadiazoles and uses thereof
Snahel Patel, South San Francisco, CA (US); Mohammad A. Mandegar, South San Francisco, CA (US); David Sperandio, South San Francisco, CA (US); Julio Medina, South San Franciso, CA (US); Ulhas Bhatt, South San Francisco, CA (US); Alok Nerurkar, South San Francisco, CA (US); and Tien Widjaja, South San Francisco, CA (US)
Assigned to Tenaya Therapeutics, Inc., South San Francisco, CA (US)
Filed by Tenaya Therapeutics, Inc., South San Francisco, CA (US)
Filed on Dec. 23, 2022, as Appl. No. 18/087,933.
Application 18/087,933 is a division of application No. 17/731,949, filed on Apr. 28, 2022, granted, now 11,578,066.
Application 17/731,949 is a continuation of application No. PCT/US2020/066439, filed on Dec. 21, 2020.
Claims priority of provisional application 63/064,516, filed on Aug. 12, 2020.
Claims priority of provisional application 63/027,602, filed on May 20, 2020.
Claims priority of provisional application 62/951,853, filed on Dec. 20, 2019.
Prior Publication US 2023/0143804 A1, May 11, 2023
Int. Cl. C07D 417/14 (2006.01)
CPC C07D 417/14 (2013.01) 20 Claims
 
1. A compound having the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:
X1 is S;
Ra is selected from the group consisting of H, halogen, and C1-3 alkyl;
R1 is

OG Complex Work Unit Chemistry
R3 is H or alkyl;
R4 is selected from the group consisting of alkyl, —(SO2)alkyl, —(SO2)alkyleneheterocyclyl, —(SO2)haloalkyl, —(SO2)haloalkoxy, —(SO2)cycloalkyl, and —(SO2)N(alkyl)(R3); and
R5 is aryl; or
R4 and R5 together with the atom to which they are attached form a heterocyclyl, optionally substituted with one or more halogen, alkyl, haloalkyl, alkoxy, and haloalkoxy.